OasisLMS

An Algorithmic Panel-Based Approach to Molecular Diagnostics in Sinonasal Tumors

Tuesday, October 28^th, 2025

11:00am-12:00pm ET

www.acmgeducation.net

Course Description

An Algorithmic Panel-Based Approach to Molecular Diagnostics in Sinonasal Tumors.

Molecular diagnostics is becoming increasingly essential in the diagnosis of sinonasal malignancies. Ontario Health (Cancer Care Ontario) funds molecular testing in sinonasal tumors with an algorithmic approach to case work-up. We will present our institutional experience in implementing the testing from the molecular lab to the oncology clinic.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing, head and neck oncogenesis, and the clinical impact of molecular test results. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentations followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

• Explain the role of molecular diagnostics in the accurate diagnosis and classification of sinonasal malignancies, and integrate this knowledge into diagnostic evaluation and treatment planning.
• Evaluate the clinical relevance of molecular testing for sinonasal malignancies and apply this information to enhance patient care strategies.

Moderator

Jason Saliba, PhD Instructor, Washington University School of Medicine

Presenters:

	Aaron Pollett, MD, FRCPC Anatomic Pathologist, Mount Sinai Hospital Co-Director, Division of Diagnostic Medical Genetics, Mount Sinai Hospital Provincial Head, Pathology and Laboratory Medicine Program, Ontario Health - Cancer Care Ontario Associate Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto
	Elan Hahn, MD, FRCPD Anatomic and Molecular Pathologist, Mount Sinai Hospital Assistant Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto
	Enrique Sanz Garcia, MD. PhD Medical Oncologist, Princess Margaret Cancer Centre Assistant Professor, Department of Medicine, University of Toronto
	Ezra Hahn, MD, FRCPC Radiation Oncologist - Clinician Investigator, Radiation Medicine Program Princess Margaret Cancer Centre, University Health Network Assistant Professor, Department of Radiation Oncology, University of Toronto

Planning Committee:

Beth Pitel, MS, CG (ASCP)

Gordana Raca, MD, PhD, FACMG

Manuela Benary, PhD

Jason Saliba, PhD

Jane Radford, MHA, CHCP

Claudia Barnett 

CME AMA PRA Category 1^TM

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians.

ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.

*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re- selling, or distributing healthcare products used by or on patients.

All relevant financial relationships listed have been mitigated.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for healthcare professionals who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare professional should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.